Patients receiving opioid treatment for chronic pain, many of whom were hospitalized with medical complications of substance abuse, were asked to complete a screening questionnaire to help validate a simple self-administered survey. Questions relating to tobacco abuse and prior treatment for drug and alcohol abuse distinguished patients with addiction and pain from opioid-treated chronic pain patients.
Introduction
A ddiction is a chronic lifelong disease, with hospitalizations for trauma, infections, and pain [1] . The transition from frequent abuse of substances to addiction, in which the patient is unable to control the adverse medical and legal consequences of substance abuse, is not understood [2] . Physicians are ill prepared to evaluate substance use and abuse in pain patients [3] . Undertreatment of pain in patients with a history of substance use may lead to addiction. On the other hand, patients with a history of addiction, when surveyed, said they would abuse drugs to achieve adequate pain control [4] . Moreover, those patients identified their prior pain treatment as a contributing cause for their addiction [5] . There are growing concerns that easier availability of controlled substances for pain treatment may be fueling an epidemic of drug abuse [6] . The ability to identify patients at risk before initiating opioid treatment might help to provide earlier treatment to addicted patients at risk for problems with opioid therapy.
Medication compliance with opioid therapy and use of illegal substances is an underrecognized problem in chronic pain patients. In a series of patients with chronic pain who submitted to drug screening, 21% had concealed their use of psychotropic substances from their physicians [7] . The relationship between compliance and possible substance abuse and addiction is particularly complex in patients with chronic pain taking opioids. Noncompliance with opioid treatment may be a warning of possible active substance abuse. In fact, while the incidence of drug addiction may be low as a consequence of opioid therapy, the likelihood of substance abuse occurring in a population of pain patients treated with opioids may be as high as 27% [8] .
Opioids have an important role in the treatment of noncancer chronic pain [9] . While small series have documented successful methadone treatment for pain in patients with substance abuse, less is known about the identification and management of substance abuse as a complication of opioid treatment [10] . Chronic pain patients who are not able to control their use of prescribed opioids may request specific opioids for treatment. Patients who develop substance abuse during pain treatment often request specific short-acting opioids. Oxycodone preparations have been identified as the "drugs of choice" for substance-abusing patients [11] . However, the failure of a particular opioid to control a patient's pain does not necessarily imply that that patient has active substance abuse. Pseudoaddiction can occur in some chronic pain patients who are prescribed subanalgesic doses of short-acting opioids [12] . These patients often demonstrate behaviors similar to those of substance-abusing patients in their search for adequate pain control.
It may be more useful in the treatment of the pain patient with a history of substance abuse to identify how the opioid is used rather than which opioid is used [13] . The inability of a pain patient to control their use of pain medication suggests possible reactivation of substance abuse. Patients who are unable to comply with treatment guidelines, who lose prescriptions, who miss appointments, and whose pain complaints escalate as opioid doses are increased may be developing active substance abuse. Random drug screening for the presence of prescribed and absence of other nonprescribed substances may be necessary to identify potential problems with opioid therapy in patients with a history of pain and substance abuse [14] . However, drug testing in an office setting requires a number of chain-of-custody procedures to prevent adulteration and misinterpretation of screening results. Opioid treatment agreements, while used to provide information for patients about the risks of opioid treatment, how treatment will be monitored, and referral for substanceabuse treatment if substance abuse occurs, may not deter chronic pain patients with who are actively abusing opioids [15] .
Screening interviews have been useful in identifying patients with substance abuse and addiction. When interviewed by experienced counselors, patients with mental health problems reported their own substance use and abuse in more than 70% of cases [16] . Pain patients with aberrant prescription behavior also identified themselves as substance abusers when interviewed by trained substance abuse counselors [17] . In nonpsychiatric settings, patients with substance abuse/addiction may sometimes not report their problems with drugs. For patients with alcohol abuse, simple self-administered screening tools, like the Michigan Alcohol Screening Test (MAST), have helped primary care physicians intervene to prevent complications associated with harmful and hazardous alcohol consumption. These tools have been validated by testing on populations of people convicted of "driving under the influence" [18] . The development of simpler, more easily administered screening tools might allow the development of a MAST-like tool to identify pain patients at risk for substance abuse before opioid treatment was initiated.
We evaluated questionnaires that had been used to screen patients with possible substance abuse and used questions about mental health status, employment, family history of drug abuse, as well as prior treatment for drug abuse in pain patients. We also used screening questions regarding tobacco abuse derived from the CAGE [19] . Our goal was to develop a simple self-administered screening tool that would identify pain patients at risk before they received opioid treatment.
Methods
After obtaining Internal Review Board approval, a screening tool for addiction risk (STAR) consisting of 14 true-or-false questions (Table 1) was evaluated in a convenience sample of 48 chronic pain patients, 14 of whom were pain patients with a recent history of substance abuse and were hospitalized for treatment for chronic infections and/or AIDS ( Table 2 ). These patients had more problems with drug or alcohol abuse? 8. Have you ever been treated in a drug or alcohol rehabilitation facility?
14. Did any family member physically or verbally abuse you 9. Do you get pain medicines from more than one doctor? when you were a child?
All questions required yes/no answers. than three DSM-IV criteria for addiction.
Answers from pain patients with substance abuse were then compared with answers from chronic pain patients with no history of active substance abuse using chi-square analysis. Differences in survey answers between the two groups of patients were examined by multiple logistic regression and factor analysis. All but one patient received opioids for their pain. This patient, with a past history of methamphetamine addiction, refused an opioid trial for intractable facial pain. Patients with active substance abuse were treated only with methadone. Chronic pain patients with addiction histories were treated with methadone as well as other sustained-release opioid preparations. Results of opioid treatment were examined by chart review for both groups of patients at 2 months.
Results
Chi-square analysis of screening questions revealed that questions relating to tobacco abuse, prior treatment in a drug or alcohol rehabilitation facility, or treatment in another pain clinic were significantly (P < 0.05) more common in respondents who had used or were currently using heroin or cocaine (addicts). Logistic regression showed that history of treatment in a drug or alcohol rehabilitation facility was a significant predictor of addiction with a positive predictive value of 93% and a negative predictive value of 5.9%. Factor analysis revealed a close relationship among cigarette smoking, a feeling of smoking too much, and a history of treatment in a drug or alcohol rehabilitation facility.
Discussion
In this preliminary evaluation of a screening tool, we found that questions related to prior treatment of substance abuse and cigarette dependence could distinguish patients who had pain and substance abuse with dependence from patients who had pain without a substance abuse history.
Questions that related to smoking helped identify substance abusers from pain patients on chronic opioids. Our findings support other observations, which showed greater polysubstance abuse in methadone-treated patients who abused tobacco [20] . Since substance abuse is a chronic relapsing disease, it is not surprising that the STAR question about prior substance abuse treatment helped to identify pain patients with substance abuse. We also confirmed earlier observations that prior treatment for substance abuse is a risk factor for the development of opioid abuse in chronic pain patients.
Psychosocial factors associated with dependence disorders were not different in the two groups of pain patients. History of emotional or physical abuse, family history of substance abuse, mood disorders, and unemployment were similar in both groups of patients we tested. We found that many risk factors for substance abuse did not distinguish chronic pain patients from those with pain and substance abuse. Our patients, many of whom were hospitalized with complications of intravenous drug abuse, still failed to show any differences from chronic pain patients in many psychosocial areas associated with drug addiction.
Our sample of chronic pain patients gathered from a large inner-city hospital may not be representative of other outpatient chronic pain practices. It is also possible that our group of patients with pain and substance abuse self-selected to participate in the survey. This sampling bias might overrepresent patients who admitted to prior treatment for drug abuse. Nevertheless, the STAR questionnaire supported observations from other screening studies that suggest tobacco abuse is predictive for active substance abuse.
We took the questions that had the highest predictive value for substance abuse and incorporated them into our pain intake questionnaire. Asking patients about their concerns over excessive smoking and if they had prior treatment for a substance abuse disorder identified pain patients at risk that we would have otherwise missed in our practice. By identifying patients at risk, appropriate evaluation of the status of their addictive disorders can be recorded as part of their pain history.
This self-administered survey tool has been helpful in identifying chronic pain patients at risk for subsequent problems with opioid treatment. We hope that further interest in this area will eventually lead to better self-administered screen- ing tools to detect the potential for active substance abuse in patients with chronic pain.
